Estela de Oliveira Lima1, Adriana Camargo Ferrasi1, Andreas Kaasi2. 1. Universidade Estadual Paulista Júlio de Mesquita Filho - FMB - Depto. Clínica Médica, Botucatu, SP - Brazil. 2. Santa Casa de Misericórdia de São Paulo - Instituto de Pesquisa, Inovação Tecnológica e Educação, São Paulo, SP - Brazil.
Regenerative medicine is an interdisciplinary branch of the biomedical sciences that is
showing, through the transposition of basic research into the clinic, great potential
for therapeutic application, and the field is consequently becoming an important
frontman for Translational Medicine. The essence of regenerative medicine consists of
the repair or replacement of tissues and organs in which there is structural and
functional deficiency. With a view of achieving this objective, several approaches have
been proposed, including therapies that include genes, cells, biologic and synthetic
scaffolds, which may or may not take part of a tissue engineering
strategy.[1] When dealing with
synthetic scaffolds, it is possible to manipulate and control structural and mechanical
properties, nonetheless, it is not possible to guarantee the same functional capacity as
natural tissue.[2] In addition, one of
the great challenges is minimizing the risk of immunogenic reactions triggered by the
repair scaffold’s composition.[3] Owing
to the challenges associated with the reestablishment on a functional and structural
level of the cell microenvironment, the interest in scaffolds based on natural
extracellular matrix (ECM) has increased considerably.With a view of obtaining a biomaterial closely approximating tissues or organs having
suffered damage, be it structural or functional, yet at the same time presenting safety
from an immunological point of view, a new technology for clinical applications of ECM
has been proposed - the decellularization of tissues and organs from human or animal
donors. This technology makes use of physical, chemical and/or biochemical methods to
eliminate cells from the target tissue/organ, be it xenogeneic or allogeneic, whose
antigens represent an elevated risk of immunogenic reaction. The process seeks to ensure
immunologic safety and the preservation of basic structural and functional components of
the ECM, such as proteins, collagen and glycosaminoglycans (GAGs). The end product is a
three-dimensional ECM scaffold with analogous shape to the original tissue, with
preserved ultrastructural architecture and with greater biocompatibility and potential
of tissue regeneration when compared to synthetic scaffolds.[4]Pericardial tissue, mainly of bovine origin, has been widely used in cardiac surgery,
whether for substitution of cardiac valves or for the repair of congenital disorders.
Its fibroserous structure, rich in elastic fibres and collagen bundles, bestows upon the
pericardium an elevated resistance to mechanical stress, and this resistance, together
with the capability of uniform suture retention, represent essential characteristics for
application in cardiovascular surgeries.[5,6]With a view of reducing the probability of immunogenic response and rejection of the
graft, the pericardium may be submitted to different treatments, among others the tissue
fixation using glutaraldehyde, which is routinely used. While this method leads to lower
immunogenicity of the tissue, the cytotoxicity and propensity of calcifications are two
important inconveniences associated with this technique.[7,8] Faced with these
problems, other methods are being developed to improve on the safe utilization of
pericardium in cardiac surgery, including decellularization. One of the most established
techniques for this purpose is the treatment of the tissue using ionic detergents, such
as sodium dodecyl sulfate (SDS). Whereas this decellularization agent is capable of
removing undesirable natural components, such as antigenic molecules, it may also lead
to structural alterations in the pericardial ECM; the loss of GAGs and important
signaling proteins being notable examples. The structural damage caused by the treatment
with SDS may impair the ideal in situ or in vitro
recellularization of the scaffold, as well as altering the mechanical properties of the
matrix, such as elasticity and extensibility.[9]The original work presented by Wollmann et al.[10] in this issue promotes the approach of human pericardium
decellularization using a reduced quantity of detergent for application as a
cardiovascular patch. The work presents itself with a view of minimizing the impact of
the technique and to obtain a human ECM of better quality, non-toxic and that may retain
as much as possible the original architecture and composition. The proposed methods
exhibit a considerable removal of cell components, including DNA, the presence of which
was reduced to approximately one-third of the original content. The tissue was also
assessed with respect to cytotoxicity, and it was shown that no cytotoxic effects were
seen in vitro. This observation brings a great stimulus for the even
deeper investigation of the technique, such as the undertaking of in
vivo tests with a view of future clinical application. Moreover, the
treatment employed did not alter the composition of the pericardium with respect to the
components elastin (qualitative assessment) and collagen (quantitative and qualitative
assessment). The treatment did present a significant quantitative reduction in GAGs,
which is well known from the literature when the decellularization is performed using
SDS detergent (revised by Scarritt et al.[11]). Despite the structural changes with respect to GAGs, the
biomechanical behavior of the matrix was similar to that of fresh tissue, and this
enables use in the treatment of tissues that suffer intense mechanical loads, such as
those encountered in the cardiovascular system.We observe that one of the field’s great challenges is to unmask the best method of
obtaining intact scaffolds. For that purpose, the concentration of the reagents can be
modulated to guarantee the ideal ECM composition, and when it is optimized on the basis
of the philosophy of “less is more”, the reagents fail considerably in removing
completely cell debris, containing cellular DNA. Conversely, when the concentrations
used are higher, the opposite is true.[12]. Considering that the success of the techniques of
decellularization is directly associated to minimal change in composition, structure and
mechanics of tissues, the work of Wollmann et al.[10] is in line with the requirements of perfecting the methods of
obtaining decellularized pericardium.In the article, Wollmann et al.[10]
investigate mainly the effect of a concentration of SDS described as “low”, of 0.1%
(w/v). That concentration is unquestionably low compared to the concentration of 1% used
in, for example, decellularization of porcine kidneys.[13] Other authors have adopted the descriptor “low
concentration” for 0.5%, also for porcine kidneys.[14] The concept of “low concentration” should be understood in the
context of the tissue to be decellularized. For example, 0.1% may be a low concentration
for a sub-millimetric tissue, such as pericardium, whereas 0.5% may equally be low for a
centrimetric organ, such as the kidney. In addition to the challenge of customizing the
concentration to the tissue to be decellularized, the variability between donors hampers
the standardization of a scalable decellularization process and suggests that the path
to clinical translation requires a customized and not necessarily standardized
approach.The use of patches in cardiac surgery is already a well-established practice, however,
the most widely used biological material is of xenogeneic origin and is not submitted to
the process of decellularization, increasing the risk of surgical
reinterventions.[3,15] The prospect of employing a
decellularized pericardial patch, whose structural components are satisfactorily
preserved and the antigenic molecules properly eliminated, is consequently of great
interest for clinical application. These characteristics have the potential to enhance
the signaling in the tissue for the recruitment and adhesion of cells from the recipient
patient’s own tissue, to maintain ideal mechanical characteristics, in addition to
reducing the immunogenicity of the graft.[16] All this would elevate the durability of the graft, favor adequate
tissue regeneration and reduce the propensity to fibrosis and calcification, improving
the quality of life of the patient. Considering that cardiovascular disease is the
driver of the main causes of death worldwide (31%),[17] developing strategies that lead to products biocompatible for
this application and more similar to natural tissue is of great importance to
regenerative medicine and, as a consequence, new alternatives are emerging in the quest
for an ideal cardiac biomaterial.
Authors: Kamal Hany Hussein; Kyung-Mee Park; Kyung-Sun Kang; Heung-Myong Woo Journal: Mater Sci Eng C Mater Biol Appl Date: 2016-05-16 Impact factor: 7.328
Authors: Nafiseh Poornejad; Nima Momtahan; Amin S M Salehi; Daniel R Scott; Cory A Fronk; Beverly L Roeder; Paul R Reynolds; Bradley C Bundy; Alonzo D Cook Journal: Biomed Mater Date: 2016-03-10 Impact factor: 3.715
Authors: Traci M Ashcraft; Karen Jones; William L Border; Pirooz Eghtesady; Jeffrey M Pearl; Phillip R Khoury; Peter B Manning Journal: Ann Thorac Surg Date: 2008-04 Impact factor: 4.330
Authors: Leigh G Griffiths; Leila H Choe; Kenneth F Reardon; Steven W Dow; E Christopher Orton Journal: Biomaterials Date: 2008-06-02 Impact factor: 12.479